Vertex Pharmaceuticals, Inc.

Nicholas LoConte

Jean-Damien Charrier

Steven John Durrant

John R Studley

Pierre-Henri Storck

Robert Michael Hughes

Benjamin Joseph Littler

David Andrew Siesel

Paul Angell

Francoise Yvonne Theodora Marie Pierard

Armando Urbina

Carl Zwicker

Timothy E Barder

Steve John Durrant

The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; solid forms of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I-1: wherein the variables are as defined herein. Additionally, the compounds of this invention have formula II: or a pharmaceutically acceptable salt thereof, wherein the variables are as defined herein.

Compounds useful as inhibitors of ATR kinase

Growing community of inventors

Winthrop, MA, United States of America

Nicholas LoConte